Grape Seed Compound Kills Leukemia Cells
Headlines (Scroll down for complete stories):
1. Grape Seed Compound Kills Leukemia Cells
2. Bone Drugs Tied to Esophageal Cancer
3. Antioxidants Relieve Pain of Chronic Pancreatitis
4. Steady Blood Sugar Levels May Slow Mental Decline
5. Weight Loss Surgery Improves Men’s Sexual Function
1. Grape Seed Compound Kills Leukemia Cells
A natural compound extracted from grape seeds makes laboratory leukemia cells commit suicide, according to a new study by the University of Kentucky. When exposed to the extract, 76 percent of the leukemia cells were dead within 24 hours.
The extract forces leukemia cells to commit “apoptosis,” or cell suicide, which is a kind of programmed cell death that cells in the body undergo either in the normal course of growth and development or when something goes wrong with them. Leukemia and other cancers block the cell signaling pathway that allows apoptosis — this is how cancer keeps the defenses of the body at bay. Grape seed extract activates a protein called JNK that regulates the apoptotic pathway and allows damaged cells to commit suicide.
Grape seed extract has already shown beneficial activity in other laboratory cancer cell lines, including breast, skin, lung, and prostate cancers. Before the new study, however, no one had tested the effects of grape seed on hematological cancers, and neither had anyone found the exact mechanism involved.
“What everyone seeks is an agent that has an effect on cancer cells but leaves normal cells alone, and this shows that grape seed extract fits into this category,” said study author Xianglin Shi, Ph.D., who emphasized that research is still in an early stage. Hematological cancers, including leukemia, caused almost 54,000 deaths in 2006, making them the fourth leading cause of cancer death in the United States.
Editor's Note:
2. Bone Drugs Tied to Esophageal Cancer
Merck's popular osteoporosis drug Fosamax and other similar drugs may carry a risk for esophageal cancer, a Food and Drug Administration official said on Wednesday.
Diane Wysowski of the FDA's division of drug risk asessment said researchers should check into potential links between so called bisphosphonate drugs and cancer.
In a letter in Thursday's New England Journal of Medicine, Wysowski said since the initial marketing of Fosamax, known generically as alendronate, in 1995, the FDA has received 23 reports in which patients developed esophageal tumors.
Typically, two years lapsed between the start of the drug and the development of esophageal cancer. Eight patients died, she reported.
In Europe and Japan, 21 cases involving Fosamax have been logged, with another six instances where Procter & Gamble's Actonel or risedronate and Didronel or etidronate, and Roche's Boniva (ibandronate) may have been involved. Six of those people died.
Esophagitis, which is an inflammation of the lining of the tube carrying food to the stomach, is already know to be a side effect of the drugs, which is why patients are instructed to remain upright for at least a half hour after taking them.
In addition, Wysowski said, doctors should avoid prescribing the drugs to people with Barrett's esophagus, which is a change in the lining that leads to the stomach. It is often found in people with acid reflux disease and itself increases the risk of cancer.
In November the FDA said that clinical trial data showed no overall risk of heart rhythm problems in patients taking bisphosphonates.
However, the FDA also said it was aware of conflicting findings in other studies and was considering whether conducting further studies to investigate the risk were feasible.
The drugs aim to treat bone-weakening osteoporosis by increasing bone mass. An estimated 10 million Americans, mostly women, have osteoporosis.
Copyright Reuters
Editor's Note:
3. Antioxidants Relieve Pain of Chronic Pancreatitis
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage). Pain is the major problem in 90 percent of patients with CP and currently, there is no effective medical therapy for pain relief. Gastroenterology is the official journal of the American Gastroenterological Association (AGA) Institute.
In this placebo-controlled, double blind trial, 127 patients, ages 30.5+/-10.5, were assigned to placebo or antioxidant groups. After six months, the reduction in the number of painful days/month was significantly higher in the antioxidant group, compared with the placebo group (7.4±6.8 versus 3.2±4, respectively). The reduction in the number of analgesic tablets/month was also higher in the antioxidant group (10.5±11.8 versus 4.4±5.8, respectively). Furthermore, 32 percent and 13 percent of patients became pain free in the antioxidant and placebo groups, respectively; the beneficial effect of antioxidants on pain relief was noted early at three months.
"Abdominal pain, the predominant symptom in patients with CP, is difficult to treat. The main reason for a largely ineffective medical treatment is that the mechanism of pain in CP is not well understood," said Pramod Kumar Garg, MD, DM, of the All India Institute of Medical Sciences, New Delhi and lead author of the study. "We are encouraged by our findings, as significant improvement was noted with antioxidants in respect to all the parameters of pain in this study. In addition, reduction in pain resulted in fewer man-days lost, thus providing functional employment gain to the patients. The findings should spur further research in this exciting area."
There are two important implications of this study — the fact that measures of oxidative stress were increased initially and decreased subsequently after supplementation with antioxidants suggests that there is a state of heightened free radical mediated injury in CP, and that injury is reversible. Second, with regard to pain management, this trial showed that antioxidant therapy is effective for pain relief in patients with CP. This assumes significance since no effective medical therapy exists for pain relief for such patients.
Visit www.gastro.org/patient for more patient information about pancreatitis.
Editor's Note:
4. Steady Blood Sugar Levels May Slow Mental Decline
Maintaining blood sugar levels, even in the absence of disease, may be an important strategy for preserving cognitive health, suggests a study published by researchers at Columbia University Medical Center (CUMC). The study appeared in the December issue of Annals of Neurology.
Senior moments, also dubbed by New York Times Op-Ed columnist David Brooks as being "hippocampically challenged,” are a normal part of aging. Such lapses in memory, according to this new research, could be blamed, at least in part, on rising blood glucose levels as we age. The findings suggest that exercising to improve blood sugar levels could be a way for some people to stave off the normal cognitive decline that comes with age.
"This is news even for people without diabetes since blood glucose levels tend to rise as we grow older. Whether through physical exercise, diet or drugs, our research suggests that improving glucose metabolism could help some of us avert the cognitive slide that occurs in many of us as we age," reported lead investigator Scott A. Small, M.D., associate professor of neurology in the Sergievsky Center and in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Medical Center.
Although it is widely known that the early stages of Alzheimer’s disease cause damage to the hippocampus, the area of the brain essential for memory and learning, studies have suggested that it is also vulnerable to normal aging. Until now, the underlying causes of age-related hippocampal dysfunction have remained largely unknown.
Previously, using high-resolution brain imaging, Dr. Small and his colleagues discovered that decreasing brain function in one area of the hippocampus, called the dentate gyrus, is a main contributor of normal decline in memory as we age.
This new study looked at measures that typically change during aging, like rising blood sugar, body mass index, cholesterol and insulin levels. The research found that decreasing activity in the dentate gyrus only correlated with levels of blood glucose.
“Showing for the first time that blood glucose selectively targets the dentate gyrus is not only our most conclusive finding, but it is the most important for 'normal' aging- that is hippocampal dysfunction that occurs in the absence of any disease states. There have been many proposed reasons for age-related hippocampal decline; this new study suggests that we may now know one of them," said Dr. Small.
“Beyond the obvious conclusion that preventing late-life disease would benefit the aging hippocampus, our findings suggest that maintaining blood sugar levels, even in the absence of diabetes, could help maintain aspects of cognitive health. More specifically, our findings predict that any intervention that causes a decrease in blood glucose should increase dentate gyrus function and would therefore be cognitively beneficial,” said Dr. Small.
The new findings also suggest that one way in which physical exercise could improve memory is via lowering glucose levels. Dr. Small’s previous imaging studies in humans and in mice have documented that among all hippocampal subregions, physical exercise causes an improvement in dentate gyrus function.
“By improving glucose metabolism, physical exercise also reduces blood glucose. It is therefore possible that the cognitive enhancing effects of physical exercise are mediated, at least in part, by the beneficial effect of lower glucose on the dentate gyrus. Whether with physical exercise, diet or through the development of potential pharmacological interventions, our research suggests that improving glucose metabolism could be a clinically viable approach for improving the cognitive slide that occurs in many of us as we age,” concluded Dr. Small.
Editor's Note:
5. Weight Loss Surgery Improves Men’s Sexual Function
Sexual dysfunction that commonly occurs in morbidly obese men improves after weight loss surgery, according to a new study.
"Sexual dysfunction should be considered one of the numerous potentially reversible complications of obesity," the study team concludes.
Dr. Ramsey M. Dallal, from Albert Einstein Healthcare Network, Philadelphia, and colleagues measured the degree to which 97 morbidly obese men suffered from sexual dysfunction and then analyzed the change in sexual function after substantial weight loss following gastric bypass surgery.
Before surgery, the morbidly obese men had significantly lower sexual function relative to that of a previously published reference control group of men before surgery, the investigators report.
After losing an average of two thirds of their excess weight, men experienced significant improvements in sexual function, with the amount of weight loss predicting the degree of improvement.
"We estimate that a man who is morbidly obese has the same degree of sexual dysfunction as a nonobese man about 20 years older," the investigators report. "Sexual function improves substantially after gastric bypass surgery to a level that reaches or approaches age-based norms."
"Sexual function is an important aspect to quality of life and is now well documented to be a reversible condition," Dallal explained.
SOURCE: Journal of the American College of Surgeons, December 2008.
Copyright Reuters
Editor's Note:
Editor's Notes:
- Key Nutrients Protect Against Cancer
- Keep Your Bones Strong Your Entire Life
- Discover the Hidden Health Benefits of Vitamins and Supplements
- Doctor Says Protect Your Memory Before It's Too Late
- Keep the Sizzle in Your Sex Life as You Age
- Diabetes is Epidemic. Protect Yourself
- You Can Be a Stroke Victim and Don't Know It
- Hormone Therapy Can Fix 10 Chronic Diseases
- Special: Join Dr. Blaylock on a Cruise of the Mediterranean
Newsmax.com
4152 West Blue Heron Blvd, Ste 1114
Riviera Beach, FL, 33404 USA
506881